Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAE102 in healthy postmenopausal women
NCT06908707Phase 1Completed
- Sponsor
- Laekna
- Start
- Apr 2025
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LAE102 (4 arms), sponsored by Laekna. Primary endpoints: Serious Adverse Events at 8 weeks and Treatment Emergent Adverse Events at 8 weeks. Started Apr 2025; status: completed.
02
Drugs
LAE102
Beyond the preview
Go deeper on NCT06908707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06908707.